BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
Evidence level: registry entry; no results posted
BRIDGE, a registered early phase 1 trial of anakinra added to the donor lung preservation solution to study primary graft dysfunction, sponsored by Northwestern University.
As of . Primary source: ClinicalTrials.gov NCT07410312.
Summary
The ClinicalTrials.gov entry describes a randomised early phase 1 study with an estimated 20 participants in which the study drug, an IL-1 receptor antagonist, is injected into the solution in which donor lungs are kept before transplantation. The registry lists the primary outcome as primary graft dysfunction after lung transplant. This is an early post-transplant condition, not chronic lung allograft dysfunction, and the record is included because it was requested for the trial watchlist. The entry gives an estimated start date of 1 October 2026 and the status not yet recruiting. No results are posted.
Details
- registry
- ClinicalTrials.gov
- registryId
- NCT07410312
- registryTitle
- BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
- sponsor
- Northwestern University
- registryStatus
- not yet recruiting
- phase
- Early Phase 1
- studyType
- interventional
- enrolment
- 20 (estimated)
- startDate
- 2026-10-01 (estimated)
- primaryCompletionDate
- 2027-08 (estimated)
- intervention
- Anakinra (drug)
- condition
- Lung Transplant Recipient
- registryLastUpdatePosted
- 2026-08-21
- registryRead
- 2026-10-10
Sources and links
Known gaps in this record
- acronym: not shown in the registry entry
- results: none posted in the registry
- participating centres and investigators: not recorded
- link to a CLADsolve centre record: not made
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.